미디어 커버리지정책 발언· 사건 전체3건2개 미디어
정부

Transfer of a Premarket Notification (510(k)) Clearance-Questions and Answers; Guidance for Industry and Food and Drug Administration Staff; Availability

Federal Register Notices

Nivis AI 요약

On November 20, 2026, the U.S. Food and Drug Administration issued two new guidance documents in the Federal Register. The first is a set of draft and revised draft product‑specific guidances for industry, published in Volume 91, No. 223, pages 75332‑75334. The second is a guidance for industry and FDA staff that provides questions and answers on transferring a Premarket Notification (510(k)) clearance, appearing on pages 75334‑75336 of the same issue. Both documents are available for public review under the respective docket numbers.

Public Domain
이 매체는 공공·자유 라이선스로 본문을 직접 표시합니다.

[Federal Register Volume 91, Number 223 (Friday, November 20, 2026)]
[Notices]
[Pages 75334-75336]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2026-23668]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2024-D-1528]

Transfer of a Premarket Notification (510(k)) Clearance--
Questions and Answers; Guidance for Industry and Food and Drug
Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of a final guidance titled ``Transfer of a Premarket
Notification (510(k)) Clearance--Questions and Answers.'' This guidance
provides information on the most frequently asked questions regarding
the transfer or sale of a 510(k) clearance from one 510(k) holder to
another.

DATES: The announcement of the guidance is published in the Federal
Register on November 20, 2026.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2024-D-1528 for ``Transfer of a Premarket Notification (510(k))
Clearance--Questions and Answers.'' Received comments will be placed in
the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document titled
``Transfer of a Premarket Notification (510(k)) Clearance--Questions
and Answers'' to the Office of Policy, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5441, Silver Spring, MD 20993-0002. Send one self-
addressed adhesive label to assist that office in processing your
request.

FOR FURTHER INFORMATION CONTACT: Erica Takai, Center for Devices and
Radiological Health, Food and Drug Administration, 301-796-6353; or
Phillip Kurs, Center for Biologics Evaluation and Research, Food and
Drug Administration, 240-402-7911.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a document titled ``Transfer
of a Premarket Notification (510(k)) Clearance--Questions and
Answers.'' This guidance provides information on the most frequently
asked questions regarding the transfer or sale of a 510(k) clearance
from one 510(k) holder to another. An owner or operator of an
establishment who is engaged in the manufacture, preparation,
propagation, compounding, assembly, or processing of a device intended
for human use is generally required to register the establishment and
submit listing information for all devices in commercial
distribution.\1\ Under section

[[Page 75335]]

510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its
implementing regulations, any person required to register under section
510 (21 U.S.C. 360) and 21 CFR 807.20 must generally submit a premarket
notification submission, or ``510(k),'' if the device is being
introduced into commercial distribution for the first time, or the
device is one that the person currently has in commercial distribution
or is reintroducing into commercial distribution, but that is about to
be significantly changed or modified in design, components, method of
manufacture, or intended use.\2\
---------------------------------------------------------------------------

\1\ 21 CFR 807.20(a); see FD&C Act subsections 510(b), 510(i),
and 510(j). Any foreign establishment engaged in the manufacture,
preparation, propagation, compounding, or processing of a device
that is imported or offered for import into the United States is
required to register and list in conformance with the procedures in
21 CFR 807.40, 21 CFR 807.41, and subpart B of 21 CFR part 807. The
registration requirement does not apply to owners or operators that
are exempt under section 510(g) of the FD&C Act or subpart D of 21
CFR part 807.
\2\ See section 510(k) of the FD&C Act; see also section 513(i),
21 CFR 807.20, 807.81(a), and FDA's guidance documents ``The 510(k)
Program: Evaluating Substantial Equivalence in Premarket
Notifications,'' ``Deciding When to Submit a 510(k) for a Change to
an Existing Device,'' and ``Deciding When to Submit a 510(k) for a
Software Change to an Existing Device.''
---------------------------------------------------------------------------

When a 510(k) clearance for a specific device is sold or
transferred from one person to another, if the new 510(k) holder is
engaged in any of the activities requiring listing, 21 CFR 807.25
requires the new 510(k) holder to list their device in FDA's electronic
device registration and listing system.\3\ When listing, if the device
is not significantly changed or modified in design, components, method
of manufacture, or intended use,\4\ the new 510(k) holder must enter
the original FDA-assigned premarket submission number unless submitting
a new 510(k), in which case the new 510(k) holder would supply the new
FDA-assigned premarket submission number, in FDA's electronic device
registration and listing system.\5\ If the new 510(k) holder has
significantly changed or modified the device in design, components,
method of manufacture, or intended use, the new 510(k) holder must
generally submit a new 510(k), and, when listing following clearance of
the new 510(k), would enter the new FDA-assigned premarket submission
number in FDA's electronic device registration and listing system.\6\
The new 510(k) holder must, if not previously entered into an operation
described in 21 CFR 807.20(a), register within 30 days after entering
into such an operation and submit device listing information, including
the FDA-assigned cleared 510(k) premarket notification submission
number,\7\ at that time.\8\ When a 510(k) clearance for a specific
device is sold or transferred from one person to another, the labeler
must submit an update to the information required by 21 CFR 830.310 by
using the Global Unique Device Identification Database (GUDID) if such
information (for example, the name of the labeler) has changed.\9\ If
you fail to register, list, update GUDID information, or submit a
marketing application when required, your device may be considered
adulterated and/or misbranded.\10\
---------------------------------------------------------------------------

\3\ 21 CFR 807.25.
\4\ For discussion about changes or modifications to existing
devices that could require submission of a new 510(k), see FDA's
guidance document titled ``Deciding When to Submit a 510(k) for a
Change to an Existing Device'' and ``Deciding When to Submit a
510(k) for a Software Change to an Existing Device.''
\5\ The new 510(k) holder need not submit a new 510(k) because
the new 510(k) holder is not proposing ``to begin the introduction
or delivery for introduction into interstate commerce for commercial
distribution'' of the device. See 21 CFR 807.81(a) and 42 FR 42523
(August 23, 1977); see also 21 CFR 807.85(b)(2) (applies to those
distributors and repackagers who are exempt from submitting a 510(k)
if it was filed by another person).
\6\ 21 CFR 807.25.
\7\ Id.
\8\ 21 CFR 807.22(a). See 21 CFR 807.22 for other registration
and listing timing requirements.
\9\ 21 CFR 830.310(a)(1) and 830.330(b)(``The labeler of a
device shall submit to FDA an update to the information required by
Sec. 830.310 whenever the information changes. The updated
information must be submitted no later than the date a device is
first labeled with the changed information. If the information does
not appear on the label of a device, the updated information must be
submitted within 10 business days of the change.'').
\10\ See FD&C Act sections 501(f)(1)(B), 502(a)(1), 502(o), and
502(t)(2).
---------------------------------------------------------------------------

A notice of availability of the draft guidance appeared in the
Federal Register of June 5, 2025 (90 FR 23937). FDA considered comments
received and revised the guidance as appropriate in response to the
comments, including clarifying terminology and further explaining
510(k) holder requirements.
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on ``Transfer of a Premarket Notification
(510(k)) Clearance--Questions and Answers.'' It does not establish any
rights for any person and is not binding on FDA or the public. You can
use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations.

II. Electronic Access

Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This guidance document is also
available at https://www.regulations.gov, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics. Persons unable to download an electronic copy of
``Transfer of a Premarket Notification (510(k)) Clearance--Questions
and Answers'' may send an email request to [email protected] to
receive an electronic copy of the document. Please use the document
number GUI00001808 and complete title to identify the guidance you are
requesting.

III. Paperwork Reduction Act of 1995

While this guidance contains no new collection of information, it
does refer to previously approved FDA collections of information. The
previously approved collections of information are subject to review by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995 (PRA) (44 U.S.C. 3501-3521). The collections of information
in the following table have been approved by OMB:

------------------------------------------------------------------------
21 CFR part; guidance; or FDA
form Topic OMB control No.
------------------------------------------------------------------------
807, subpart E................ Premarket 0910-0120
notification.
807, subparts A through D..... Electronic Submission 0910-0625
of Medical Device
Registration and
Listing.
------------------------------------------------------------------------

[[Page 75336]]

Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-23668 Filed 11-19-26; 8:45 am]
BILLING CODE 4164-01-P

공식 발표 ↔ 매체 보도

진보 성향0

보도 없음

중도 성향0

보도 없음

보수 성향0

보도 없음